8-K: FibroGen Reports Strong First Quarter Revenue Growth Driven by Roxadustat and One-Time Revenue

FibroGen's first quarter revenue increased by 55% year-over-year, driven by strong roxadustat sales in China and a one-time revenue recognition from the AstraZeneca agreement termination.

Summary

• FibroGen reported a 55% year-over-year increase in total revenue for the first quarter of 2024, reaching $55.9 million, compared to $36.2 million in the same period last year.
• This growth was primarily driven by a 26% increase in roxadustat net product revenue in China, which reached $30.5 million, and a one-time drug product revenue of $25.7 million from the termination of the US/RoW AstraZeneca agreement.
• Roxadustat volume in China grew by 39% year-over-year, with total roxadustat net sales in China reaching $79.4 million.
• The company's net loss for the quarter was $32.9 million, or $0.33 per share, an improvement from a net loss of $76.7 million, or $0.81 per share, in the first quarter of 2023.
• FibroGen's cash, cash equivalents, investments, and accounts receivable totaled $214.7 million as of March 31, 2024, and the company projects its cash runway into 2026.
• Topline data from two late-stage clinical trials of pamrevlumab in pancreatic cancer are expected in mid-2024 and the third quarter of 2024.
• The company also reported compelling Phase 1 data for FG-3246, a CD46 targeted antibody drug conjugate, in metastatic castration-resistant prostate cancer.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved financial performance, and promising clinical trial data. The company's cash runway into 2026 provides financial stability. However, the company is still loss-making and reliant on roxadustat sales in China.

Positives

• The company experienced a significant 55% increase in total revenue year-over-year.
• Roxadustat sales in China showed strong growth, with a 26% increase in net product revenue and a 39% increase in volume.
• The company recognized a substantial one-time revenue of $25.7 million.
• The net loss improved significantly compared to the same quarter last year, decreasing from $76.7 million to $32.9 million.
• The company has a strong cash position of $214.7 million, which is expected to fund operations into 2026.
• Positive Phase 1 data for FG-3246 in prostate cancer was reported, showing a median radiographic progression free survival of 8.7 months.
• Roxadustat continues to be the number one brand based on value share in the anemia of CKD market in China.

Negatives

• The company still reported a net loss of $32.9 million for the quarter.
• The company is reliant on roxadustat sales in China for a significant portion of its revenue.
• The company is still in the clinical trial phase for pamrevlumab and FG-3246, with no guarantee of regulatory approval.
• The company experienced a decrease in cash and cash equivalents from $113.7 million to $105.7 million.

Risks

• The company's future success is dependent on the successful completion of clinical trials and regulatory approvals for its drug candidates.
• The company's financial performance is heavily reliant on the sales of roxadustat in China.
• There are risks associated with the development of new drugs, including potential safety issues and lack of efficacy.
• The company faces competition from other pharmaceutical companies developing similar treatments.
• The company's cash runway is projected into 2026, but future capital raises may be required.

Future Outlook

FibroGen expects to report topline data from two late-stage clinical trials of pamrevlumab in pancreatic cancer in the coming months and has reaffirmed its cash runway into 2026. The company also anticipates an approval decision for roxadustat in chemotherapy-induced anemia in China in the second half of 2024.

Management Comments

• We are off to a strong start in 2024 marked by the recent release of compelling Phase 1 data on FG-3246, our CD46 targeted antibody drug conjugate, in metastatic castration-resistant prostate cancer and continued robust growth of our roxadustat business in China, said Thane Wettig, Chief Executive Officer, FibroGen.
• Looking ahead, we expect to report topline data from our two late-stage clinical trials of pamrevlumab in pancreatic cancer in the coming months.
• In addition, we have a strong balance sheet and reaffirm our cash runway into 2026.

Industry Context

This announcement highlights FibroGen's progress in both its commercial and clinical programs. The strong revenue growth from roxadustat in China underscores the importance of the Chinese market for the company. The upcoming topline data from the pamrevlumab trials will be closely watched by investors and competitors in the pancreatic cancer space. The positive Phase 1 data for FG-3246 positions FibroGen as a potential player in the prostate cancer treatment market.

Comparison to Industry Standards

• FibroGen's 55% revenue growth in Q1 2024 is significantly higher than the average growth rate for many biopharmaceutical companies, which often see single-digit or low double-digit growth.
• The 26% growth in roxadustat sales in China is a strong performance compared to other companies operating in the same market, where growth rates can vary widely depending on market penetration and competition.
• The reported median radiographic progression free survival of 8.7 months for FG-3246 in metastatic castration-resistant prostate cancer is a promising result, and will be compared to other treatments in the same space such as enzalutamide and abiraterone.
• The cash runway into 2026 is a positive sign for investors, as it provides financial stability for the company's ongoing clinical trials and commercialization efforts. Many companies in the same space have a shorter cash runway and are more reliant on capital raises.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and improved financial performance.
• Employees may feel more secure due to the company's strong cash position and positive outlook.
• Customers in China will continue to have access to roxadustat for the treatment of anemia.
• Suppliers may benefit from the company's increased revenue and continued operations.
• Creditors may view the company as a lower risk due to its improved financial performance and cash runway.

Next Steps

• FibroGen will report topline data from the PanCAN Precision PromiseSM Phase 2/3 study of pamrevlumab in metastatic pancreatic cancer in mid-2024.
• FibroGen will report topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer in 3Q 2024.
• FibroGen expects an approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.
• FibroGen will present initial data from a Phase 1 investigator-initiated combination study of FG-3246 with enzalutamide at ASCO 2024.
• FibroGen anticipates initiating a Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in 2H 2024.
• FibroGen anticipates filing an IND for FG-3175 (anti-CCR8 mAb) in 2025.

Key Dates

Keywords

FibroGen, roxadustat, pamrevlumab, FG-3246, pancreatic cancer, prostate cancer, anemia, China, clinical trials, revenue, biopharmaceutical